Blood Product Development

The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.

IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry. With a mission to accelerate innovation for a healthier world and a vision to power smarter healthcare for everyone, everywhere, IQVIA leverages unparalleled data, transformative technology, and deep healthcare expertise to drive better patient outcomes. Operating in over 100 countries with approximately 88,000 employees, IQVIA supports pharmaceutical, biotech, medtech, public health, and government organizations with a comprehensive portfolio of services and solutions. The company is recognized for its Connected Intelligence™, healthcare-grade AI, and commitment to sustainability, innovation, and evidence-based insights that shape the future of healthcare globally. IQVIA is also dedicated to reducing health inequities and driving sustainable change through innovation, collaboration, and data-driven solutions, partnering with organizations worldwide to address complex healthcare challenges.

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Vascarta Inc. is a pharmaceutical company that has developed a patented topical/transdermal delivery platform aimed at improving the bioavailability of drugs, particularly curcumin, a compound known for its anti-inflammatory and antioxidant properties. The company focuses on addressing unmet medical needs through innovative formulations that enhance therapeutic efficacy and patient outcomes.

Stream Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class targeted therapeutics for acute neurotrauma and chronic neurodegenerative diseases. The company is dedicated to revolutionizing cerebrovascular repair and developing novel solutions for neurotrauma and neurodegeneration, including conditions such as stroke, traumatic brain injury, and Alzheimer's disease.

FluidForm Bio™ is revolutionizing medicine through its patented FRESH™ technology, which enables the bioprinting of living human tissue for advanced cell therapy and disease treatment. Founded in 2018, the company integrates innovations in 3D printing, synthetic biology, and AI to create tissue that closely resembles natural human tissue, aiming to improve patient outcomes and transform healthcare.

FiteBac Technology/FiteBac Pharma's innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21. FiteBac K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction.

Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. The company focuses on purpose-driven innovation to empower healthcare professionals and enhance patient outcomes across various medical fields.

Qidni Labs Inc. is dedicated to making dialysis technology more accessible for patients with kidney failure. With a mission to provide innovative solutions, they aim to serve the 10 million patients who currently lack access to dialysis treatment.

GreenLifeTech is dedicated to improving sustainability by extending the shelf life of fresh produce, thereby reducing food waste and promoting healthier living. In addition, the technology is applicable to preserving transfusion blood. Their initial innovative product, FreshDefend™, is a smart countertop system that can extend the life of fruits and vegetables by up to five times without the use of harmful chemicals. The company is committed to environmental sustainability, reducing agricultural waste, and supporting communities through charitable donations.

Altra Inc. is at the forefront of revolutionizing infusion therapy with its innovative Altra Infusion System. The company is dedicated to addressing the critical challenges in the infusion industry, such as mechanical failures, flow issues, and false alarms, which contribute to a significant portion of medication errors and adverse drug events. Altra's mission is to ensure patient safety and improve healthcare delivery through advanced technology solutions.

The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) charitable organization dedicated to advancing the rapid deployment of innovative medical technologies that improve the health of both military personnel and civilians. MTEC fosters military-civilian partnerships and collaboration among businesses, federal agencies, academic institutions, and other stakeholders. Through a flexible Other Transaction Agreement (OTA), MTEC expedites the development and commercialization of cutting-edge medical solutions, bridging the gap between research and real-world application. With over 700 members, MTEC has facilitated more than $1.3 billion in federal funding, 358 awarded projects, and a robust pipeline of 141 products.

SanaHeal is dedicated to developing next-generation bioadhesive technologies inspired by nature to solve significant challenges in healthcare. Their innovative solutions are designed to adhere to wet and uneven surfaces, providing rapid and robust adhesion for various medical applications.

UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.

Advanced BioScience Laboratories, Inc. (ABL) is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics, and other biologic products. ABL leverages its expertise in product development, GMP manufacturing, and immunological testing to support the development of candidate vaccines and therapeutics through preclinical and clinical stages. The company is involved in producing and testing oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines.